BTK inhibitors and Venetoclax have a synergistic mechanism of action in that BTK inhibitors have a preferential activity on dividing CLL cells in the lymph nodes, whereas Venetoclax exerts its activity preferentially on resting CLL cells, particularly in peripheral blood [68]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.